Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform

Rhea-AI Summary

Aon plc (NYSE: AON) has announced a strategic investment in eMed Population Health, Inc., a company specializing in GLP-1 programs for obesity treatment. The investment follows Aon's successful implementation of eMed's GLP-1 weight management program for its U.S. workforce, which demonstrated impressive results with 22.4 pounds average weight loss and a 95% retention rate among 1,200+ participants over six months.

The partnership aims to scale eMed's digital-first healthcare platform, which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support. This strategic move aligns with Aon's broader initiative to develop comprehensive GLP-1 solutions and advisory capabilities for employers seeking to address obesity and chronic conditions through medication-based interventions.

Positive

• Successful pilot program showed 22.4 pounds average weight loss with 95% retention rate
• Over 1,200 participants enrolled in Aon's GLP-1 program within six months
• Strategic investment will help scale eMed's digital healthcare platform to reach more employers
• Partnership expected to help reduce long-term employer health costs

Negative

• High costs associated with GLP-1 medications require strategic consideration from employers

Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings

DUBLIN, Aug. 18, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership will enhance employer sponsored access to GLP-1 therapies and scale solutions for obesity.

The investment follows the launch earlier this year of Aon's subsidized GLP-1 weight management benefit program for its U.S. workforce – developed by eMed – which has delivered strong adherence, high retention and sustainable results for the firm's colleagues. In the sixth months since Aon's program launched, more than 1,200 people have registered and the firm has seen an average of 22.4 pounds lost with a retention rate of 95 percent.

With this investment, eMed will continue to increase distribution of its digital-first healthcare platform — which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support—to reach more employers and patients.

"As the leader of Aon's People Organization, I know how important it's been to include GLP-1 coverage as part of our own U.S. Total Rewards strategy," said Lisa Stevens, Chief Administrative Officer for Aon. "When you see the benefits it brings to people you work with every day, it really underscores how the decisions employers make today shape the future health and performance of our workforces and our businesses."

Stevens added: "This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace in helping employers reduce long-term health costs while improving the quality of life for their people. By aligning innovation with behavior change and accountability, together we can deliver sustainable results at scale."

The collaboration marks a major milestone in eMed's mission to deliver effective and sustainable care through an integrated, data-driven experience, while expanding its provider network, behavioral health tools and market reach.

"Today marks a game-changing partnership between Aon and eMed and is a win for both payers and participants," said Linda Yaccarino, CEO of eMed Population Health, Inc. "Our shared vision of market transformation is validated and accelerated by the investment from Aon. This strategic investment in eMed further enables our firm to play an active role in offering a differentiated global solution focused on medication adherence – helping employers reduce long-term health costs while improving quality of life for their people."

Aon continues to build a complimentary suite of GLP-1 solutions, industry-leading experience and advisory capabilities for clients. In April, Aon unveiled findings from its multi-year analysis of U.S. commercial health claims data, which evidenced the transformative potential of GLP-1 medications in managing obesity and improving health outcomes. 

"The rise of GLP-1 medications and its cost has sparked significant strategic considerations from employers looking to address obesity and other chronic conditions," said Farheen Dam, Head of Health for North America at Aon. "We know that GLP-1s are not a one size fits all strategy. This is why data, modelling and strategic guidance from our clinical, actuarial and pharmacy teams help employers build GLP-1s strategies that fit their population and objectives."

About eMed
eMed® is the world's first end-to-end GLP-1 care platform built on Empathetic AI™. From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at www.eMed.com. 

About Aon
Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.

Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon's newsroom and sign up for news alerts here.

Media Contacts

eMed
Matt Gorman
mgorman@targetedvictory.com

Aon
mediainquiries@aon.com
Toll-free (U.S., Canada and Puerto Rico): +1 833 751 8114
International: +1 312 381 3024 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aon-announces-strategic-investment-in-emed-to-scale-glp-1-population-health-platform-302532181.html

SOURCE Aon plc

FAQ

What are the results of Aon's GLP-1 weight management program in 2025?

Aon's program achieved 22.4 pounds average weight loss with a 95% retention rate, attracting over 1,200 participants in six months.

Why did Aon (NYSE: AON) invest in eMed Population Health?

Aon invested in eMed to scale GLP-1 obesity solutions, enhance employer-sponsored access to GLP-1 therapies, and help reduce long-term health costs while improving employee quality of life.

What services does eMed's digital-first healthcare platform offer?

eMed's platform combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support for GLP-1 therapy management.

How is Aon addressing the GLP-1 medication trend for employers?

Aon is building a suite of GLP-1 solutions with industry-leading experience and advisory capabilities, using data, modeling, and strategic guidance from clinical, actuarial, and pharmacy teams to help employers develop targeted strategies.

What was the enrollment rate for Aon's GLP-1 program in 2025?

More than 1,200 people registered for Aon's GLP-1 weight management program within the first six months of launch.